Robin E. Norris, MD, MS, MPH, is a pediatric cancer specialist (hematology and oncology) and Director of the Pediatric Developmental Therapeutics Program, Division of Pediatric Hematology and Oncology, at University Hospitals Rainbow Babies & Children's Hospital. She is Assistant Professor, Pediatrics, Case Western Reserve University School of Medicine.
Dr. Norris is board certified in pediatrics and pediatric hematology and oncology. Her special interests include developmental therapeutics, pharmacology and treatment of relapsed cancer. She joined the UH Rainbow Babies & Children's Hospital staff in 2012.
Dr. Norris graduated from Stanford University, Stanford, Calif., with a bachelor’s degree in human biology. She earned her medical degree from the University of Pennsylvania School of Medicine, Philadelphia, Pa. After completing her residency in pediatrics at the University of California, San Francisco, Calif., she completed her studies for a Master of Public Health with a concentration in epidemiology at the University of California, Berkeley, Calif. She obtained her fellowship training in hematology and oncology at Children’s Hospital of Philadelphia, Philadelphia, Pa., and in 2010 completed a Master of Science in translational research at the University of Pennsylvania School of Medicine, Institute for Translational Medicine and Therapeutics.
A dedicated researcher, Dr. Norris’ interest is in advancing the treatment of children with recurrent cancer. She currently is Principal Investigator on a trial evaluating a novel antibody for pediatric cancers and Principal Investigator for the effort to expand access to early clinical trials for children, adolescents and young adults with relapsed or refractory cancers through the Developmental Therapeutics Program at UH Rainbow Babies & Children’s Hospital.
Since 2008 Dr. Norris has completed four other clinical trials of new treatments for cancer in children. She has published her research in leading medical journals and presented at national medical meetings. She currently serves as auditor for the Children’s Oncology Group, the national pediatric cancer research consortium.
She is a member of the American Society of Hematology, American Society of Pediatric Hematology-Oncology, American Society of Clinical Oncology and the American Association of Cancer Research.
Awards and Recognitions
Foerderer Award for International Study, Children’s Hospital of Philadelphia, 2010
Young Investigator Award, Alex’s Lemonade Stand, 2008
Recurrent cancer in children
American Board of Pediatrics - Pediatric Hematology-Oncology
American Board of Pediatrics - Pediatrics
Education & Training
1997, Stanford University
Medical / Professional School(s)
2001, University of Pennsylvania School of Medicine
2004, Pediatrics - University of California (San Francisco) Medical Center
2008, Pediatric Hematology/Oncology - Children's Hospital of Philadelphia
Developmental Therapeutics, Pharmacology, Treatment of Relapsed Cancer
UH Rainbow Babies and Children's Hospital
Department of Pediatrics-Hematology and Oncology
11100 Euclid Ave
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
For calendar year 2012, Robin Norris, MD did not disclose any Outside Relationships with Industry.